Rana McKay, MD

GU Oncology Now

In Part 2 of this video series, Rana McKay, MD, Medical Oncologist and Associate Professor of Medicine, UC San Diego Health, highlights the results of a few studies that support the use of frontline immunotherapy for favorable-risk metastatic RCC, as well as progress in identifying predictive biomarkers for patients who are likely to respond to immunotherapy.Among the trials discussed are HCRN GU16-260, OMNIVORE, and TITAN. Additionally, the OPTIC trial is noted as an attempt to use transcriptomic signatures to risk stratify and allocate patients to specific immunotherapy combination therapies.View Dr. McKay&rsquo;s other comments on advanced RCC management, including <a href="https://guoncologynow.com/post/dr-rana-mckay-on-the-current-treatment-paradigm-for-metastatic-rcc" target="_blank" rel="noopener">the Current Treatment Paradigm</a>, <a href="https://guoncologynow.com/post/dr-rana-mckay-on-second-line-therapy-and-beyond-for-metastatic-rcc" target="_blank" rel="noopener">Second-line Therapy and Beyond</a>, <a href="https://guoncologynow.com/post/dr-rana-mckay-on-novel-therapies-and-sequences-for-metastatic-rcc-treatment" target="_blank" rel="noopener">Novel Therapies and Sequences</a>, and <a href="https://guoncologynow.com/post/dr-rana-mckay-on-radiation-therapy-and-radiopharmaceuticals-for-rcc" target="_blank" rel="noopener">Radiation Therapy and Radiopharmaceuticals</a>.

Dr. Rana McKay on Frontline Immunotherapy for Metastatic RCC

Advanced Renal Cell Carcinoma

Rana McKay, MD, highlights the results of a few studies that support the use of frontline immunotherapy for favorable-risk metastatic RCC.

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe